Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
Head to Head Contrast: Retractable Technologies (NYSE:RVP) & Interpace Biosciences (OTCMKTS:IDXG)
Head to Head Analysis: Dynatronics (NASDAQ:DYNT) versus Interpace Biosciences (OTCMKTS:IDXG)
Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
Interpace Biosciences Earnings Drop
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates
Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
Interpace Biosciences Announces Path Forward in Letter to Shareholders
Interpace Biosciences Announces CFO Leadership Transition
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
Interpace Biosciences (NASDAQ:IDXG) Shares Gap Up to $2.98
Brokerages Anticipate Interpace Diagnostics Group Inc (NASDAQ:IDXG) to Post -$1.64 Earnings Per Share
Next Generation Cancer Diagnostics: Technologies and Global Markets (2019-2025) - ResearchAndMarkets.com
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
Clovis Rubraca Data, And Other News: The Good, Bad And Ugly Of Biopharma
$5.6 Billion Worldwide Veterinary Reference Laboratory Industry to 2025 - Featuring GD Animal Health, Boehringer Ingelheim & Zoetis Among Others - ResearchAndMarkets.com
Luminex Corp (DE) (LMNX) Q2 2020 Earnings Call Transcript | The Motley Fool
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
Clostridium Diagnostics - Global Market Analysis and Outlook 2020-2027: Revised with COVID-19 Growth Deviations - ResearchAndMarkets.com